Skip to content

3D 系统

US · DDD #3666 按市值排名 上市于 2011
2.76 -0.20 -6.76%
实时 - 追踪5344个代码 - 心跳于37秒前 · 2026-10-16 19:54

✦ 量化股权信号 计算方式说明

涨跌不一/平稳
  • 最近一期（2026/Q3）披露持股的机构数量减少了1家。
  • 机构持股总比例基本持平。

机构持股

机构持股比例
76.29% +0.02pp
机构数量
242 -1
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund43.62%
Hedge Fund22.39%
Public Company5.52%
Individual/Insider3.43%
Private Company1.85%
Insurance Company1.67%
Family Office/Trust1.16%
Other20.29%

主要股东 截至 2026-06-30

BlackRock 8.18% · 13.59M 股
State Street Global Advisors 7.99% · 13.27M 股
Vanguard Capital Management, LLC 4.70% · 7.81M 股
Aigh Capital Management, LLC 4.38% · 7.27M 股
Two Sigma Investments, LP 3.95% · 6.56M 股
The Bank of Nova Scotia 3.16% · 5.25M 股
D. E. Shaw & Co., L.P. 2.56% · 4.26M 股
Marshall Wace LLP 2.37% · 3.93M 股
Geode Capital Management, LLC 2.26% · 3.76M 股
Needham Investment Management, LLC 2.12% · 3.53M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 22次买入 · 28次卖出

姓名职务持股比例
Jeffrey Graves Chief Executive Officer 0.74%
Phyllis Nordstrom Executive VP, Chief People Officer & Chief Administrative Officer 0.43%
Jim Kever Independent Director 0.34%
Charles Hull Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus 0.31%
Reji Puthenveetil Executive Vice President of Industrial Solutions 0.29%
Thomas Erickson Independent Director 0.24%
Kevin Moore Independent Director 0.19%
Joseph Zuiker Executive Vice President of Engineering & Operations 0.16%
Charles McClure Independent Chairperson 0.14%
John Tracy Independent Director 0.14%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-09-16 Jeffrey Graves Chief Executive Officer Open Market Disposition -42,686 $3.55
2026-09-16 Phyllis Nordstrom Executive VP, Chief People Officer & Chief Administrative Officer Open Market Disposition -30,000 $3.58
2026-09-07 Charles Hull Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus Sale to Issuer -4,943 $3.38
2026-09-07 Jeffrey Graves Chief Executive Officer Sale to Issuer -39,959 $3.38
2026-09-07 Phyllis Nordstrom Executive VP, Chief People Officer & Chief Administrative Officer Sale to Issuer -47,396 $3.38
2026-09-07 Andrew Wright Senior VP of General Counsel & Corporate Secretary Sale to Issuer -5,818 $3.38
2026-09-07 Reji Puthenveetil Executive Vice President of Industrial Solutions Sale to Issuer -15,984 $3.38
2026-09-07 Joseph Zuiker Executive Vice President of Engineering & Operations Sale to Issuer -6,689 $3.38
2026-08-19 Jeffrey Graves Chief Executive Officer Open Market Disposition -115,500 $3.26
2026-05-13 Jim Kever Independent Director Other Acquisition +45,731 --
2026-05-13 Thomas Erickson Independent Director Other Acquisition +45,731 --
2026-05-13 Kevin Moore Independent Director Other Acquisition +45,731 --
2026-05-13 Charles McClure Independent Chairperson Other Acquisition +45,731 --
2026-05-13 John Tracy Independent Director Other Acquisition +45,731 --
2026-05-13 Malissia Clinton Independent Director Other Acquisition +45,731 --
2026-05-13 Vasant Padmanabhan Independent Director Other Acquisition +45,731 --
2026-05-13 Claudia Drayton Independent Director Other Acquisition +45,731 --
2026-04-13 Charles Hull Co-Founder, Executive VP, CTO of Regenerative Medicine & Director Emeritus Sale to Issuer -4,102 $1.98
2026-04-13 Jeffrey Graves Chief Executive Officer Sale to Issuer -30,500 $1.98
2026-04-13 Phyllis Nordstrom Executive VP, Chief People Officer & Chief Administrative Officer Sale to Issuer -1,626 $1.98

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:54:31 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

3D 系统 讨论区 0 条评论

发表评论